EBD Group is part of the KNect365 of Informa PLC


This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Informa
 
Biotech Showcase 2015 EBD Group Demy-Colton
Share/Follow Us
Share this:
Follow this event:

Biotech Showcase™ Press Releases

News for Biotech Showcase™ 2017 will be available soon.

January 27, 2016Biotech Showcase™ 2016 reports record high attendance this year A record number of life science industry executives attended the eighth annual Biotech Showcase investor and networking conference, held January 11–13 in San Francisco. More than 2,500 executive-level delegates representing qualified private and public equity investors, industry analysts, bankers, pharmaceutical and biotechnology industry executives attended from 1,600...  more ►

December 22, 2016Biotech Showcase™ 2016 will be "home base" for investment community in San Francisco in January The eighth annual Biotech Showcase investor and networking conference will be held in San Francisco during the healthcare industry's busiest week of the year, January 11–13, 2016. The event acts as home base for innovative mid-small cap and private life sciences companies and the public, private and strategic investors eager to meet with them. Over 300 innovative comp...  more ►

November 10, 2015The 8th Annual Biotech Showcase will celebrate life sciences innovations in January 2016 amid the largest healthcare investor conference of the year The eighth annual Biotech Showcase investor and networking conference will be held January 11–13, 2016 in San Francisco, CA at Parc 55 San Francisco - A Hilton Hotel. The event is expected to bring together 2,100+ attendees representing the life science industry's most enterprising and pioneering biotech companies and major players in the drug development arena. The pr...  more ►


partnering360® Blog

May 19, 2016 How drug development is like your diet If you’re like me, you read the dailies. Companies run the gamut from riding high and plump on investment infusion to rock hard abs times when they’re all muscle and no fat, and, possibly back again. With summer coming, it occurred to me that drug development cycles are very much like dieting,... more ►

May 12, 2016 From Zika virus to fast, high quality clinical trials: Puerto Rico’s Consortium for Clinical Investigation (PRCCI) Situated just 1,200 miles from the mainland US, a hotspot of clinical trial activity is being established on a small island paradise. If you haven’t heard of the Puerto Rico Consortium for Clinical Investigation (PRCCI), you should. What this organization is doing in clinical research trials for... more ►

April 29, 2016 Digital Health: Still a brave new world At this year’s BIO-Europe Spring® panel on “The Convergence of Therapeutics and Digital Health,” two panelists from big pharma joined two from Scandinavian digital health companies, agreeing that while the platform for digital health technologies is strong in Europe, much... more ►

April 19, 2016 The characteristics of a “winning” biotech startup QureTech Bio AB, a startup developing first line drugs to combat antibiotic resistance and infectious diseases, won the Start-up Slam: Sweden biotech competition at BIO-Europe Spring® 2016 in Stockholm, Sweden earlier this month. QureTech Bio AB participated in the pitching competition sponsored by... more ►

April 5, 2016 Images of BIO-Europe Spring® 2016 in Stockholm [See image gallery at www.partnering360.com] more ►



partnering360:Insight Latest headlines from partnering360:Insight

May 18, 2016 Italy’s A. Menarini IFR aims to expand into the US and Japan Giammario Piras, corporate licensing director at A. Menarini IFR, explains why and how Italy's largest drug maker plans to expand into the US and Japanese markets. more ►

May 18, 2016 BeyondSpring Pharmaceuticals outlines Plinabulin plans, wants marketing partner BeyondSpring Pharmaceuticals' chief medical officer Ramon Mohanial outlines plans for advancing the group's immuno-oncology pipeline, with ongoing Phase II and III trials of its most promising assets. more ►

May 17, 2016 Accellta CEO says israeli stem cell specialist seeks global partners Itzchak Angel, CEO of Israeli stem cell specialist Accellta, discusses the group's stem cell culturing process and future expansion plans including a planned USD 15 million capital raising exercise and ongoing search for corporate partners. more ►

May 17, 2016 AngioDesign tailoring next-generation ACE inhibitors Mario Ehlers, Chairman of drug discovery group Angio-Design (UK) explains why the design of specific domain-selective ACE inhibitors is expected to produce next-generation drugs that are safer and more effective—and generate blockbuster returns. more ►

May 17, 2016 4SC AG’s CSO outlines epigenetics strategy 4SC AG Chief Science Officer says the German cancer drug developer is conducting a Phase II trial of lead candidate ACE inhibitor resminostat in cutaneous T-cell lymphoma. more ►



Arrow Up

Follow this event:
Sign up now
For news and updates

Privacy Policy and Cookies Terms of Use

Home | Contact Us | Site Map
See more upcoming conferences ►

EBD Group's Family of Events

© 2009–2016 EBD Group
Privacy Policy and Cookies
Terms of Use